A randomized placebo controlled trial testing the effect of Zoledronic Acid on Hip osteoarthritis

2025-521435-36-01 Protocol Project ID: 2018030 Therapeutic use (Phase IV) Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol Project ID: 2018030

Overview

Sponsor-declared trial summary

Phase Therapeutic use (Phase IV)
Status Authorised, recruitment pending
Participants planned 70
Countries 1
Sites 1

Osteoarthritis of the Hip

Key facts

Sponsor
Martina Hansens Hospital AS
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Decision date (initial)
2025-05-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Osteoarthritis of the Hip

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Martina Hansens Hospital AS

Sponsor organisation
Martina Hansens Hospital AS
Address
Doenskiveien 8
City
Gjettum
Postcode
1346
Country
Norway

Scientific contact point

Organisation
Martina Hansens Hospital AS
Contact name
Stig Heir

Public contact point

Organisation
Martina Hansens Hospital AS
Contact name
Stig Heir

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Norway Authorised, recruitment pending 70 1
Rest of world 0

Investigational sites

Norway

1 site · Authorised, recruitment pending
Martina Hansens Hospital AS
Orthopedic, Doenskiveien 8, 1346, Gjettum

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-28 Norway Acceptable with conditions
2025-05-06
2025-05-15